First Presentation of Pooled Phase III Data Supporting Europe's Newest Partial Epilepsy Treatment

First Presentation of Pooled Phase III Data Supporting Europe's Newest Partial Epilepsy Treatment PR Newswire HATFIELD, England, October 4, 2012 HATFIELD, England, October 4, 2012 /PRNewswire/ -- ®New results for Fycompa (perampanel) presented today at leading epilepsy conference New data shared today with Europe's epilepsy community at the 10th European Congress on Epileptology (ECE) in ®London, demonstrate the efficacy of once-daily Fycompa (perampanel) in reducing partial-onset seizures, the most common form of epilepsy, and its effectiveness and flexibility of use as add-on therapy. The successful treatment of partial-onset seizures (the most common form of epilepsy) remains a significant challenge in some patients and the incidence of uncontrolled partial epilepsy remains high, despite many existing anti-epileptic [1]drugs (AEDs); between 20 - 40% of patients with epilepsy have remained poorly controlled despite these treatments. The new data supports the use of perampanel as a new therapeutic option for this hard-to-treat patient population. Results from two separate analyses of pooled data from the perampanel pivotal Phase III clinical trial programme [2]endorse the efficacy and safety of the new AED at clinically relevant doses. In addition, the results show that [3]perampanel decreased the frequency of both complex partial seizures and secondarily generalised seizures.